Lifeward Completes Oratech Acquisition and Secures Private Financing

The latest update is out from Lifeward ( (LFWD) ).

On March 25, 2026, Lifeward completed its previously announced acquisition of Oratech Pharma from Oramed, issuing 2,256,476 ordinary shares and pre-funded warrants, along with additional transaction warrants and a revenue-sharing arrangement tied to ReWalk Personal Exoskeleton sales. The deal was accompanied by structural amendments assigning the purchase agreement to Oratech Ltd., underscoring Lifeward’s push to deepen its technology portfolio and monetize its flagship mobility products.

That same day, Lifeward closed a related private financing under a securities purchase agreement, issuing $10 million in senior secured convertible notes and accompanying warrants to Oramed and other accredited investors, in a transaction exempt from U.S. registration. The non-public offering strengthens the company’s balance sheet and provides capital to integrate Oratech while avoiding immediate equity market dilution through a traditional public raise.

Also on March 25, 2026, directors Dr. John William Poduska and Randel Richner resigned from the board without any disagreement over company operations, and the board was expanded from five to eight members. Nadav Kidron, Miriam Kidron and Yehuda Reznick were appointed as new Class III, II and I directors, respectively, reshaping Lifeward’s governance and committee structure as it absorbs Oratech and advances its strategic growth plans.

The most recent analyst rating on (LFWD) stock is a Sell with a $6.50 price target. To see the full list of analyst forecasts on Lifeward stock, see the LFWD Stock Forecast page.

Spark’s Take on LFWD Stock

According to Spark, TipRanks’ AI Analyst, LFWD is a Neutral.

The score is held down primarily by weak financial performance (large ongoing losses and cash burn, plus erosion of equity). Technicals are only neutral and remain below longer-term trend levels, while valuation is constrained by negative earnings and no dividend. Corporate events add some support from regained bid-price compliance and strategic approvals, but governance and high-cost financing risks temper the upside.

To see Spark’s full report on LFWD stock, click here.

More about Lifeward

Lifeward Ltd. operates in the medical technology sector, focusing on mobility solutions such as its ReWalk Personal Exoskeleton products and related extended warranties. The company targets patients with mobility impairments and works closely with healthcare stakeholders, positioning itself at the intersection of assistive robotics, rehabilitation technology and medical devices.

Average Trading Volume: 27,676

Technical Sentiment Signal: Sell

Current Market Cap: $9.77M

For a thorough assessment of LFWD stock, go to TipRanks’ Stock Analysis page.